PD patients with GBA mutations exhibit dramatic changes in lipid concentrations in serum, including increased ceramide and sphingomyelin levels and decreased phosphatidic acid levels (Guedes et al., 2017). This evidence concerns the gene GBA1 and Parkinson disease.